Measurement of heparin in patients receiving subcutaneous heparin therapy.
Heparin assays based on four different tests of clotting function have been compared with a heparin assay utilizing the potentiating effect of heparin on anti-factor Xa in a group of patients receiving subcutaneous heparin therapy during late pregnancy. It is considered that the anti-factor Xa method is a better indication of the antithrombotic effect of heparin. In the presence of high levels of clotting factors, heparin assays based on tests of clotting function can be misleading.
D001780:Blood Coagulation Tests; D005260:Female; D006493:Heparin / Q000097:blood* / Q000627:therapeutic use; D006801:Humans; D007279:Injections, Subcutaneous; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy; D013923:Thromboembolism / Q000188:drug therapy; D013997:Time Factors
D006493:Heparin